Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 9/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700700 | 0.84 | CCR2 (0.65) | CCR2GPR35 | |
| SCHEMBL6964777 | 0.81 | CCR2 (0.49) | CCR2PTGS2RXFP1GPR35PROKR1 | |
| SCHEMBL22022199 | 0.81 | RXFP1 (0.59) | ACLYGFERRXFP1 | |
| SCHEMBL8689838 | 0.79 | ALDH1A1 (0.54) | CCR2PTGS2TDP1 | |
| SCHEMBL22004309 | 0.76 | ACLY (0.58) | ACLYCCR2TDP1 | |
| SCHEMBL22004146 | 0.76 | PTGS2 (0.60) | ACLYCCR2PTGS2PROKR1 | |
| Hydrochloric Acid SCHEMBL8689664 | 0.74 | RXFP1 (0.43) | CCR2PTGS2RXFP1 | |
| SCHEMBL8687383 | 0.72 | CCR2 (0.62) | CCR2 | |
| SCHEMBL21335592 | 0.72 | ALDH1A1 (0.45) | ACLYCCR2RXFP1GAATDP1 | |
| SCHEMBL9243077 | 0.71 | CCR2 (0.47) | CCR2PTGS2RXFP1PROKR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885CCR2 4510/4885GFER 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.